Top Markets
Coin of the day
BioLineRx Ltd. BioLineRx Ltd.

BioLineRx Ltd.

BLRX
Rang in Aktien #40526
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and... BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Aktienkurs
$0.0048574
Marktkapitalisierung
$126.82K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-21.82%
Land
IL
Handel BioLineRx Ltd. (BLRX)

Kategorie

Dividendenrendite-Verlauf für BioLineRx Ltd. (BLRX)
Dividendenrendite (TTM) von BioLineRx Ltd. (Aktienkürzel: BLRX) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für BioLineRx Ltd. (BLRX) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber